AI Summary
Prompt injection defense that is self-healing
Silmaril
- YC
Prompt injection defense that is self-healing
Best for
Teams evaluating AI product workflows / Builders comparing emerging tools / Operators tracking early category shifts
Why it matters
Primary discovery source is Y Combinator.
Key Features
- Primary public product URL is https://silmaril.dev/.
- Description: Prompt injection defense that is self-healing.
- Listed on Y Combinator as "Silmaril".
- Source description: Prompt injection defense that is self-healing.
- Source publish date is 2026-04-09.
Use Cases
- Primary discovery source is Y Combinator.
- Y Combinator mention is recent (2026-04-09).
- Primary public product URL is https://silmaril.dev/.
- Description: Prompt injection defense that is self-healing.
- Listed on Y Combinator as "Silmaril".
Why Now
Silmaril is a prompt injection defense solution that is self-healing, with its recent inclusion on Y Combinator indicating it's an emerging product worth watching.
Community Signals
Trend score
50.5
24h momentum
Rising
Facts / Signals / Inference / Unknowns
Facts
- Description: Prompt injection defense that is self-healing.
- Primary public product URL is https://silmaril.dev/.
- Listed on Y Combinator as "Silmaril".
- Source description: Prompt injection defense that is self-healing.
- Source publish date is 2026-04-09.
Signals
- Primary discovery source is Y Combinator.
- Y Combinator mention is recent (2026-04-09).
Inference
- Y Combinator inclusion suggests the product is appearing in new-launch or discovery-oriented surfaces.
Unknowns
- Documentation is not explicitly linked in the current allowed evidence set.
- No tagline is stored on the current product record.
- Pricing details are not explicitly linked in the current allowed evidence set.
- Recent changelog or release history is not explicitly linked in the current allowed evidence set.
Evidence Snapshots
Silmaril
Listed on Y Combinator as "Silmaril".
Silmaril official profile
Primary public product URL is https://silmaril.dev/.
